GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

123.53B

Vuru Grade

80.36/100

Current Price

$86.87
-0.93 (-1.06%)

Growth Price

$97.11
Undervalued by 11.79%

Stability Price

$38.51
Overvalued by 55.67%

Company Metrics

  • P/E 7.29
  • P/S 3.83
  • P/B 6.53
  • EPS 11.91
  • Cash ROIC 43.15%
  • Cash Ratio 1.76
  • Dividend 1.72 / 2.02%
  • Avg. Vol. 10.97M
  • Shares 1.65B
  • Market Cap. 123.53B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

What to Expect from Gilead Sciences, Inc.'s New CEO
Motley Fool - Feb 10, 2016
In this clip of Industry Focus: Healthcare, Motley Fool analysts Michael Douglass and Kristine Harjes are joined by contributor Todd Campbell to discuss Gilead Sciences pipeline, M&A prospects, and its new CEO. Listen to the full podcast by clicking here.
Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know
Motley Fool - Feb 10, 2016
Motley Fool healthcare contributor Todd Campbell joins healthcare analysts Michael Douglass and Kristine Harjes to dig into Gilead Sciences' (NASDAQ:GILD) fiscal 2015 financial results and management's guidance for 2016. Can the company overcome ...
Stock in Limelight: Gilead Sciences, Inc - CWRU Observer
Analyst Target Update: Gilead Sciences, Inc. (NASDAQ:GILD) - Markets Daily
Will Gilead Sciences, Inc. Continue to Dominate HIV Treatment?
Motley Fool - Feb 8, 2016
After apparently losing market share within the multibillion dollar market for medicine used to treat HIV, is Gilead Sciences' (NASDAQ:GILD) reign as the top drugmaker coming to a close? In this clip of Industry Focus: Healthcare, Motley Fool analysts ...
AbbVie and Gilead Sciences Lead 2015 Drug Sales with Humira & Harvoni
Bidness ETC - 47 minutes ago
AbbVie Inc's (NYSE:ABBV) anti-inflammatory drug, Humira, and Gilead Sciences, Inc.'s hepatitis C medicine, Harvoni, came up almost neck-and-neck as the top-selling treatments in 2015.
Instant Analysis: Gilead Sciences Inc.'s Longtime CEO Steps Down
Motley Fool - Jan 29, 2016
Gilead Sciences (NASDAQ:GILD) announced today that longtime CEO John Martin will be moving out of the corner office and taking on the role of executive chairman of the biotech giant.
Gilead Sciences, Inc – Selloff Makes GILD Stock a Serious Bargain - Investorplace.com
Gilead: Buyout Targets Abound
Seeking Alpha - Feb 9, 2016
... juggernaut Gilead Sciences (NASDAQ:GILD) plans to do in 2016 which would remove over 10% of its outstanding float at current prices.
Leerink Partners: Buy Gilead Sciences, Inc. (GILD), Be Cautious With Celgene ...
Smarter Analyst - Feb 5, 2016
After joining Leerink Partners in November, analyst Geoff Porges reinitiated coverage yesterday on major healthcare stocks. Among the equities in focus are pharmaceutical giants Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation ...
Bull Case for Gilead Sciences, Inc. (GILD) - InvestCorrectly
Gilead Sciences Inc. (GILD) Pops 3.26% for February 09 - Equities.com
International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results
Motley Fool - Feb 3, 2016
If the year ended on Groundhog Day, 2016 would be the worst year for Gilead Sciences (NASDAQ:GILD) since 2009. But the year doesn't end on Feb. 2. And Gilead's announcement of its fourth-quarter results after the market closed on Tuesday could help ...
State challenge to Gilead would hinge on untested legal theory - The Boston Globe
Buy Gilead Sciences, Inc on Bargain; Why You Can Never Go Wrong
Bidness ETC - Feb 8, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) ended 2015 as its peak year in terms of sales, roughly 60% of which were derived from a highly successful hepatitis C franchise consisting of two key drugs, Harvoni and Sovaldi.
The Pipeline: An Unappreciated Part Of Gilead's Value Story - Seeking Alpha
Sentiment Ratings For Gilead Sciences, Inc. (NASDAQ:GILD)
Investor Newswire - 3 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) has been able to get a sentiment rating of 4. This rating is given after ClosingBell.